ReviewJournal of cancer research and clinical oncology2009
Gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Review in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Correlation of serum levels of endostatin with tumor stage in gastric cancer: a systematic review and meta-analysis.BioMed research international · 2015Pooled it
- Gastric metastasis in renal cell carcinoma: a case report and systematic review.Journal of gastrointestinal cancer · 2011Pooled it
- Alternative medicines in oncology: a focus on natural products against gastric cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The Human Cytomegalovirus US31 Gene Predicts Favorable Survival and Regulates the Tumor Microenvironment in Gastric Cancer.Frontiers in oncology · 2021Article
- Genetic profiling of somatic alterations by Oncomine Focus Assay in Korean patients with advanced gastric cancer.Oncology letters · 2020Article
- Overexpression of Myosin Phosphatase Target Subunit 1 (MYPT1) Inhibits Tumor Progression and Metastasis of Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Next generation sequencing-based emerging trends in molecular biology of gastric cancer.American journal of cancer research · 2018Review
- Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients.Oncology reports · 2016Article
- The exploration of network motifs as potential drug targets from post-translational regulatory networks.Scientific reports · 2016Article
- HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer.Gut · 2016Article
- Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer.Chonnam medical journal · 2015Article
- Targeting receptor tyrosine kinases in gastric cancer.World journal of gastroenterology · 2014Review
- Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer.Archives of medical science : AMS · 2014Article
- Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.PloS one · 2014Article
- Identifying molecular drivers of gastric cancer through next-generation sequencing.Cancer letters · 2013Review
- Advanced gastric cancer: is there enough evidence to call second-line therapy standard?World journal of gastroenterology · 2012Article
- In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2012Article
- Polymorphisms of mismatch repair gene hMLH1 and hMSH2 and risk of gastric cancer in a Chinese population.Oncology letters · 2012Article
- MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Molecular cancer therapeutics · 2012Article
- Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.Journal of translational medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the second most common cause of cancer death worldwide with approximately one million cases diagnosed annually. Despite considerable improvements in surgical techniques, innovations in clinical diagnostics and the development of new chemotherapy regimens, the clinical outcome for patients with advanced gastric cancer and cancer of the GEJ is generally poor with 5-year survival rates ranging between 5 and 15%. The understanding of cancer relevant events has resulted in new therapeutic strategies, particularly in developing of new molecular targeted agents. These agents have the ability to target a variety of cancer relevant receptors and downstream pathways including the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor receptor (VEGFR), the insulin-like growth factor receptor (IGFR), the c-Met pathway, cell-cycle pathways, and down-stream signalling pathways such as the Akt-PI3k-mTOR pathway. In the era of new molecularly targeted agents this review focuses on recent developments of targeting relevant pathways involved in gastric cancer and cancer of the GEJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.